Key Takeaways Regeneron stock has dropped 21.1% YTD, underperforming the industry, sector, and S&P 500.Eylea sales face pressure from Roche's Vabysmo, while Eylea HD posts U.S. growth.Dupixent and new oncology approvals like Lynozyfic and Ordspono support Regeneron's outlook. Shares of Regeneron Pharmaceuticals ((REGN) have lost 21.1% year to date against the industry’s growth of 5.2%. The stock has also underperformed the sector and the S&P 500 Index during this time frame. While the stock has recovered so ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a price target of $640. The analyst noted that his rating is based on the strong results from Phase 3 trials for the company’s cat and birch allergy antibody cocktails. The results showed significant symptom reduction with key improvements seen in ocular itch, redness, and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best cheap stocks to buy for beginners. In a report released on September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), setting a price target of $640.00. Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week The analyst cited various factors supporting the optimistic outlook, including the promising results from its recent Phase 3 trials for the cat and birch allergy antibody ...

据卢特尼克表示，总统特朗普正在调动多个行政部门机构以实现这一目标。"我刚刚接到(卫生部长)博 比·肯尼迪的电话。我还接到了(美国医疗保险和医疗补助服务中心主任)梅赫迈特·奥兹的电话，他们都 和我说，'好吧，让我们开始推进这件事吧'。"卢特尼克在采访中补充说。 总部位于美国的吉利德(GILD.US)、百时美施贵宝(BMY.US)、强生(JNJ.US)、再生元(REGN.US)、安进 (AMGN.US)以及艾伯维(ABBV.US)，还包括总部位于欧洲的大型药企默克集团(Merck KGaA)、赛诺菲 (SNY.US)、葛兰素史克(GSK.US)、阿斯利康(AZN.US)、诺和诺德(NVO.US)、罗氏(RHHBY.US)以及诺 华(NVS.US)也收到了特朗普的来信。 "总统将会说，大型药品制造商们如果不在那边以更高的价格进行出售，就不能在这里销售。别再愿意 以那么低的价格卖给他们了。"卢特尼克在采访中表示。特朗普给药企们设定遵守该最惠国政策的最后 期限为9月29日，并且他在此之前作出了上述的坚定表态。 智通财经APP获悉，美国商务部长霍华德·卢特尼克近日在接受媒体采访时表示，总统唐纳德·特朗普正 在联合多个联邦 ...

Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent efficacy was observed across histologies with especially notable benefit in the squamous patient population where median overall survival was 22.3 months TARRYTOWN, N.Y., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced five-yea ...

Presentation Terence FlynnEquity Analyst Great. Good morning, everybody. I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst, and I'm very pleased to be hosting Regeneron to kick off our 23rd Annual Global Healthcare Conference this morning. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Today from the company, we have Len Schle ...

Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.REGN is feeling the pressure from bearish momentum. Get the market research here.Allergen-blocking antibody treatment in Cat-allergen “Ocular Challenge” TrialREGN1908 and REGN1909 are two fully human monoclonal antibodies (mAbs) targeting and blocking FelD1.In the Phase 3 trial, cat-allergic participant ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) FY Conference September 08, 2025 07:00 AM ET Company ParticipantsChris Fenimore - EVP, Finance & CFOLeonard Schleifer - Board co-Chair, President & CEOMarion McCourt - EVP & Head - CommercialConference Call ParticipantsTerence Flynn - Equity Research AnalystTerence FlynnGreat, good morning everybody. I'm Terence Flynn, Morgan Stanley's U.S. Biopharma Analyst, and I'm very pleased to be hosting Regeneron to kick off our 23rd annual Global Healthcare Conference this m ...

核心观点 - 再生元公司公布其首创过敏原阻断抗体在猫和桦树过敏原激发3期试验中的积极结果 单次给药后症状显著改善 疗效持续超过3个月 数据将支持进一步3期开发 [1][2][4][12] 临床试验结果 猫过敏试验 - REGN1908/REGN1909组合针对主要猫过敏原FelD1 在3期试验中33名患者接受单次给药 与31名安慰剂组对比 [3][4] - 主要终点眼部瘙痒降低52%(p<0.0001) 关键次要终点结膜充血减少39%(p<0.0001) 皮肤点刺反应性下降44%(p<0.0001) [4] - 在FelD1驱动型患者亚组中显示更佳疗效 眼部瘙痒减少64% 结膜充血下降49% [4] - 疗法耐受性良好 无严重治疗相关不良事件或导致试验中止的事件 [4] 桦树过敏试验 - REGN5713/REGN5715组合针对主要桦树过敏原BetV1 在3期试验中27名患者接受单次给药 与27名安慰剂组对比 [5][6][12] - 眼部瘙痒降低51%(p<0.0001) 结膜充血减少46%(p<0.0001) 皮肤点刺反应性下降44%(p<0.0001) [12] - 疗法耐受性良好 无严重不良事件或导致试验中止的事件 [12] 产品特性与优势 - 采用直接提供过敏原阻断抗体的创新方法 避免传统脱敏治疗需多次注射数年且效果不佳的问题 [2] - 单次皮下给药后8天即显示快速起效 疗效持久性达3个月以上 [2][4][12] - 此前鼻过敏原激发和环境暴露单元试验也显示类似快速深远的疗效 [4][12] 研发进展与规划 - 猫过敏项目计划2026年上半年启动额外3期开发 [4] - 桦树过敏项目计划年底前启动额外3期开发 [12] - 数据将用于支持确认性3期试验设计 [1] - 公司过敏管线还包括严重食物过敏的概念验证试验 采用BCMAxCD3双特异性抗体联合Dupixent的新方法 [7] 技术平台 - 所有抗体均采用VelocImmune技术平台开发 该平台使用基因工程小鼠产生优化全人源抗体 [9] - 该技术已产出多个FDA批准的全人源单抗 包括Dupixent、Libtayo、Praluent等 [9] 市场背景 - 猫过敏影响美国超2000万患者 其中约100万/年接受脱敏治疗 [3][4] - 桦树花粉过敏影响美国超1000万人 35%患者在接受标准治疗后仍出现中重度症状 [5] - 猫过敏原FelD1具有强附着性 可黏着衣物鞋具家具 在无猫室内环境也难以避免 [3]

公司动态 - 将于2025年9月8日东部时间上午7:00出席摩根士丹利第23届全球医疗保健会议并进行演讲 [1] - 演讲将通过网络直播进行 可在公司官网"投资者与媒体"页面访问 回放和文字记录将存档至少30天 [2] 公司业务概览 - 是一家领先的生物技术公司 专注于为严重疾病患者发明、开发和商业化变革性药物 [3] - 拥有多元化的药物研发管线 涵盖眼科疾病、过敏及炎症性疾病、癌症、心血管及代谢疾病、神经系统疾病、血液疾病、传染病和罕见病等领域 [3] 技术平台与研发能力 - 采用VelociSuite等专有技术平台 可生产优化的全人源抗体及新型双特异性抗体 [4] - 通过Regeneron遗传学中心和基因医学平台整合数据洞察 用于识别创新靶点和辅助治疗方法 [4]